×
Pharmacodynamic effects in blood and tumor tissue of eftozanermin alfa, a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist.
https://meetinglibrary.asco.org/record/189151
Monica Motwani, PhD

May 28th, 2020 - Background: Eftozanermin alfa (eftoza; formerly known as ABBV-621), a 2nd-generation tumor necrosis factor-related apoptosis-inducing ligand receptor agonist, is being evaluated in previously treated solid and hematologic malignancies (NCT03082209). In a dose-expansion cohort, patients (pts) with KRAS-mutant colorectal cancer (n = 24) and pancreatic cancer (n = 24) were evaluated at 3 dose leve...

Body composition and treatment-related toxicity in pediatric lymphoma.
https://meetinglibrary.asco.org/record/188813
Aman Wadhwa, MD, MSPH

May 28th, 2020 - Background: Body composition is an emerging predictor of toxicity and survival in older adults with cancer (Shachar, Eur J Can, 2016); however, its role in pediatric cancer is not known. We examined body composition (using computed-tomography [CT] scans at the 3rd lumbar level) in children with lymphoma (Hodgkin [HL] and non-Hodgkin [NHL]) at cancer diagnosis and examined its association with t...

Safety results from phase I/II study of the PI3Kβ inhibitor GSK2636771 (G) in combination with pembrolizumab (P) in patients (pts) with PD-1 refractory metastatic melanoma (MM) and PTEN loss.
https://meetinglibrary.asco.org/record/188806
Hussein Abdul-Hassan Tawbi, MD, PhD

May 28th, 2020 - Background: Checkpoint inhibitors (CPI) have improved survival and long-term disease control in 35-40% of pts with MM. Many pts derive no clinical benefit or progress after an initial response. Our group and others have shown that loss of the tumor suppressor protein PTEN occurs in multiple cancers, up to 30% of MM pts, activates the PI3K pathway, and correlates with decreased MM response rates...

Feasibility of evidence-based treatment of childhood acute myeloid leukemia in a Sub-Sahara Africa center.
https://meetinglibrary.asco.org/record/188753
Irene Nzamu, MBChB

May 28th, 2020 - Background: The proportion of Acute Myeloid Leukemia (AML) among childhood leukemias is putatively higher in Sub-Sahara Africa (SSA) compared to Western experiences. However, the treatment of childhood AML is challenging in SSA settings because of inadequate facilities for supportive care to deliver intensive AML regimens and, hence, high treatment-related mortality (TRM). Many pediatric oncolo...

Tolerability of radiation with concurrent temozolomide and effect on survival in chemo-refractory CNS lymphoma.
https://meetinglibrary.asco.org/record/189294
Anna Mary Brown Laucis, MD, MPhil

May 28th, 2020 - Background: There is no consensus for the treatment of central nervous system lymphoma (CNSL) refractory to first line high dose methotrexate-based chemotherapy. Whole brain radiation (WBRT) has often been used but may lead to unacceptable neurocognitive dysfunction. We examined our institutional experience with treating CNSL with radiotherapy (RT) and concurrent temozolomide (TMZ) including th...

Weekly chemotherapy instead of best supportive care alone must be considered for patients of small cell lung cancer with poor performance status.
https://meetinglibrary.asco.org/record/187715
Gunjan Shrivastav, MD

May 28th, 2020 - Background: Many patients of Small Cell Lung Cancer (SCLC) present with advanced age & comorbidities. Although chemotherapy may benefit these patients, therapy is denied due to treatment toxicities. We studied tolerability and efficacy of weekly Etoposide with carboplatin in patients unfit for 3-weekly regimen to analyze the hypothesis if small dose weekly chemotherapy can replace the current s...

Stability and visual compatibility of daunorubicin and cytarabine during Y-site administration with selected drugs.
https://meetinglibrary.asco.org/record/189185
Guillaume Sicard

May 28th, 2020 - Background: Vyxeos is a daunorubicine plus cytarabine liposome indicated in adults patient with newly diagnosed acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) and therapy-related AML (t-AML). The standard protocol is an induction phase on D1, D3 and D5 at 100 mg/m² (expressed in cytarabine) during 90 minutes followed by 2 consolidation cures at 65 mg/m² on D1 and D3. Data ...

Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-gene blood-based comprehensive genomic profiling assay.
https://meetinglibrary.asco.org/record/189377
Ryan Woodhouse

May 28th, 2020 - Background: As the availability of precision therapies expand, a well-validated blood-based comprehensive genomic profiling (CGP) assay has the potential to provide considerable value as a complement to tissue-based testing to ensure that potentially life-extending therapies are administered to the patients most likely to benefit. Comprehensive clinical and analytical validity data for blood-ba...

Enabling variant calling in challenging FFPE samples by coupling a novel library preparation chemistry with exome sequencing.
https://meetinglibrary.asco.org/record/188907
Bosun Min

May 28th, 2020 - Background: Comprehensive tumor profiling using NGS is fundamentally transforming oncology research. However, converting archival tissue samples into libraries is often challenging due to the low quantity and quality of DNA. Here we present accurate detection of variants in the human exome using the novel chemistry of the xGen Prism DNA library preparation kit, optimized for low-input and degra...

Identification of germline cancer predisposition variants during clinical ctDNA testing.
https://meetinglibrary.asco.org/record/189102
Leigh Anne Anne Stout

May 28th, 2020 - Background: Next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) is a non-invasive method to guide therapy selection for cancer patients. Identification of inherited germline cancer predisposition mutations that have significant implications for at-risk relatives may be missed during routine ctDNA testing. Allele frequency has the potential to enhance the likelihood that a mutation...

Association of CEP72 rs924607 with vincristine-induced peripheral neuropathy (PN) in patients with diffuse large B-cell lymphoma on CALGB 50303 (Alliance).
https://meetinglibrary.asco.org/record/189586
Daniel Louis Hertz, PhD, PharmD

May 28th, 2020 - Background: Pediatric patients (pts) receiving long-term vincristine treatment for acute lymphoblastic leukemia (ALL) who carry two variant alleles of CEP72 rs924607 experience more severe peripheral neuropathy (PN) at lower cumulative vincristine doses. The objective of this retrospective pharmacogenetic analysis was to determine if pts homozygous for rs924607 have increased PN risk when recei...

Pharmacogenetics findings in Brazilian cancer patients.
https://meetinglibrary.asco.org/record/189310
Luis Eduardo Werneck De Carvalho, MD, PhD

May 28th, 2020 - Background: Pharmacogenetic is the study of genetic modifications influence on drugs action. Recent studies have suggested that some genetic polymorphisms may have an influence on patient outcomes. Thus, the objective of this thesis is to evaluate the frequency of genetic polymorphisms in cancer patients. Methods: Cross-sectional study at the Oncology Center of São Paulo. The reports presented ...

Implementation of psychosocial support project in a pediatric oncology camping program.
https://meetinglibrary.asco.org/record/189116
Simone Lehwess Mozzilli

May 28th, 2020 - Background: The oncological treatment can generate psychosocial distress for patients and their families. The Beaba Camping aims to educate and empower patients and caregivers through Technology Information and Gamification. In August 2019, in the third edition of the project, a pilot of Psychosocial Support Program was implemented to provide an integrative care to 71 children and adolescents u...

Retrospective cohort study of real-world treatment patterns and overall survival in patients with chronic lymphocytic leukemia (CLL) diagnosed between 2010 to 2017 in Ontario, Canada.
https://meetinglibrary.asco.org/record/190243
Shazia Hassan

May 28th, 2020 - Background: With recent advances in treatment of CLL, it is important to understand emerging treatment patterns and associated outcomes. A population-based study was undertaken to describe the management and survival of CLL patients in Ontario, Canada. Methods: Patients diagnosed with CLL between January 1, 2010 and December 31, 2017 were identified in the Ontario Cancer Registry and linked to ...

Primary extranodal non-Hodgkin lymphoma: Clinical characteristics and outcome.
https://meetinglibrary.asco.org/record/190253
Tara Rajendran

May 28th, 2020 - Background: According to the National Cancer Registry Program, the Indian Council of Medical Research reports that the estimated Incidence rate of Non-Hodgkins Lymphoma in India is 2-3 per 100,000 people. The incidence rate of extranodal Non-Hodgkins Lymphoma (NHL) in Asia is higher than that of the United States. We illustrate a single center review of the clinical characteristics of all the p...

Immunohistochemistry analyses of LAG-3 expression across different tumor types and co-expression with PD-1.
https://meetinglibrary.asco.org/record/189651
Francine Chen, MD

May 28th, 2020 - Background: Concomitant blockade of LAG-3 and PD-1 has been shown to restore T-cell activation and enhance anti-tumor immunity in preclinical models. Clinical trials evaluating anti-LAG-3/anti-PD-1 mAb combinations or bispecific molecules are ongoing. Establishing the tumor expression profile of LAG-3 and its relationship to PD-1 will aid in patient selection and interpretation of clinical resp...

Impact of CD38 knockout in NK cells on daratumumab-mediated cytotoxicity and cellular metabolism.
https://meetinglibrary.asco.org/record/189740
Yuya Nagai, MD, PhD

May 28th, 2020 - Background: Multiple myeloma (MM) is a neoplasm of plasma cells. These cells express high levels of CD38 and are sensitive to daratumumab (DARA), a CD38-targeting monoclonal antibody. DARA kills MM cells via several mechanisms including antibody dependent cellular cytotoxicity (ADCC). Although DARA has improved the outcome of patients, CR is not achieved in all the cases. Besides, most patients...

Searching for the “exit ramp”: Bereaved caregivers (BCGs) describe discontinuation of transfusions at the end of life (EOL) for loved-ones (LOs) dying from acute myeloid leukemia (AML).
https://meetinglibrary.asco.org/record/189878
Larry Dean Cripe, MD

May 28th, 2020 - Background: Transfusions may delay hospice care. This study examined how transfusions and other factors influenced care transitions, including decisions related to hospice care, for patients with AML from diagnosis to death. Methods: Nineteen BCGs participated in semi-structured interviews about their experiences. Interviews were audio recorded, transcribed and qualitatively analyzed. Results: ...

Never too young: Retrospective study on age and racial disparity in the outcome of primary CNS Lymphoma in south Texas.
https://meetinglibrary.asco.org/record/189930
Snegha Ananth, MD

May 28th, 2020 - Background: Primary CNS lymphoma (PCNSL) is a rare malignancy, comprising only 2% of primary CNS tumors in the United States.While it’s incidence has decreased in the immunocompromised population (HIV positive) secondary to widespread access of effective anti-retroviral therapy, it is suspected that the rates are increasing among immunocompetent people aged 65+ years at a rate of approximately ...

Performance of cell-free tumor DNA testing for 101 clinical laboratories on College of American Pathologists proficiency tests.
https://meetinglibrary.asco.org/record/189748
Christina M Lockwood

May 28th, 2020 - Background: Cell-free tumor DNA or circulating tumor DNA tests are increasingly used in clinical care to detect somatic mutations from solid tumors. However, data on laboratory performance characteristics using standardized samples is limited. Methods: Well-characterized reference materials were used for the College of American Pathologists (CAP) cell-free tumor DNA proficiency testing surveys,...